Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use INLURIYO safely and effectively. See full prescribing information for INLURIYO. INLURIYO (imlunestrant) tablets, for oral use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- generic_name
- imlunestrant
- product_names
- imlunestrant
- ndc
- 0002-1717, 0002-1717-28, 0002-1717-56, 0002-1717-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en